Wesbanco Bank Inc. Sells 4,116 Shares of Novo Nordisk A/S $NVO

Wesbanco Bank Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.3% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 173,685 shares of the company’s stock after selling 4,116 shares during the period. Wesbanco Bank Inc.’s holdings in Novo Nordisk A/S were worth $11,988,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the stock. Verde Capital Management grew its position in Novo Nordisk A/S by 15.2% during the second quarter. Verde Capital Management now owns 42,837 shares of the company’s stock valued at $2,957,000 after buying an additional 5,639 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its position in Novo Nordisk A/S by 46.1% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,356 shares of the company’s stock valued at $94,000 after buying an additional 428 shares during the period. Wilson & Boucher Capital Management LLC grew its position in Novo Nordisk A/S by 2.5% during the second quarter. Wilson & Boucher Capital Management LLC now owns 53,338 shares of the company’s stock valued at $3,681,000 after buying an additional 1,320 shares during the period. Garde Capital Inc. boosted its position in Novo Nordisk A/S by 39.4% during the second quarter. Garde Capital Inc. now owns 1,185 shares of the company’s stock worth $82,000 after purchasing an additional 335 shares during the period. Finally, Sage Capital Advisors llc boosted its position in Novo Nordisk A/S by 1.7% during the second quarter. Sage Capital Advisors llc now owns 46,999 shares of the company’s stock worth $3,244,000 after purchasing an additional 765 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NVO shares. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a research report on Wednesday, August 13th. Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. HSBC lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 target price for the company. in a research report on Thursday, July 31st. Finally, Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 31st. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $81.00.

Novo Nordisk A/S Trading Up 1.2%

Shares of Novo Nordisk A/S stock opened at $54.94 on Friday. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $138.22. The company has a market cap of $245.31 billion, a price-to-earnings ratio of 15.09, a PEG ratio of 2.06 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company’s 50-day moving average price is $57.96 and its 200-day moving average price is $66.33.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.